Core Viewpoint - Hongbo Pharmaceutical (301230) forecasts a net profit attributable to shareholders of 31.2 million to 38.1 million yuan for 2025, representing a year-on-year growth of 82.64% to 123.03% [1] Group 1: Business Performance - The company has continuously deepened its main business layout and actively implemented its annual operating plan, resulting in a favorable overall business situation for 2025 [1] - Revenue from drug discovery, process research and development, and commercial production has all achieved year-on-year growth [1] Group 2: Operational Efficiency - The capacity utilization rates of its wholly-owned subsidiaries, Shanghai Hongbo Shangyi Pharmaceutical Technology Co., Ltd. and Chengdu Hongbo Zhiyuan Pharmaceutical Technology Co., Ltd., have improved to varying degrees compared to the previous year [1] - The company has enhanced operational efficiency through refined management and optimized resource allocation [1] Group 3: Strategic Development - Hongbo Pharmaceutical has strengthened platform construction and continuously improved its industrial chain service system [1] - The company has significantly enhanced its one-stop comprehensive service capability from new drug discovery to commercial production, further consolidating its strategic competitive advantage [1]
泓博医药2025年净利同比预增82.64%至123.03%